J. Matthew Hutzler, Ph.D.
Prior to joining the Q2 Solutions Bioanalytical & ADME Labs organization in 2014, Dr. Hutzler was a DMPK project lead in drug discovery for five years at Boehringer-Ingelheim Pharmaceuticals, where he worked on several project teams supporting inflammation and atherosclerosis therapeutic areas. Dr. Hutzler also held a similar position at Pfizer Inc. (St. Louis) for over five years, initially helping build an in vitro core lab. With over 15 years of experience in the drug metabolism field, Dr. Hutzler’s ADME research has focused on characterizing atypical enzyme kinetics for cytochrome P450 enzymes, structure-activity relationships for inhibition of CYP2D6, mechanistic understanding of inhibition of cytochrome P450 enzymes, extrapolation of in vitro metabolism data for human clearance and pharmacokinetic predictions, understanding species differences and variability of aldehyde oxidase activity using hepatocytes, and most recently, investigating novel in vitro models to address slowly metabolized drug molecules. Dr. Hutzler has published over 30 peer-reviewed articles in high impact journals and three book chapters.

Dr. Hutzler earned his Ph.D. in pharmaceutical sciences from West Virginia University under the direction of Dr. Timothy S. Tracy and completed a post-doctoral fellowship at Pharmacia with Dr. Larry Wienkers.